Hansa Biopharma AB (publ) (LON:0RC7)
40.00
+3.64 (10.01%)
At close: Feb 11, 2026
Hansa Biopharma AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 701.08 | 405.28 | 732.06 | 1,496 | 651.34 |
Short-Term Investments | - | - | - | - | 237.62 |
Cash & Short-Term Investments | 701.08 | 405.28 | 732.06 | 1,496 | 888.96 |
Cash Growth | 72.99% | -44.64% | -51.07% | 68.31% | -35.47% |
Accounts Receivable | 53.87 | 144.97 | 78.03 | 42.96 | 9.71 |
Other Receivables | 35.52 | 17.49 | 15.73 | 24.22 | 13.53 |
Receivables | 89.4 | 162.46 | 93.76 | 67.18 | 23.24 |
Inventory | 6.13 | 2.61 | 1.51 | 0.97 | 0.24 |
Prepaid Expenses | - | 2.84 | 3.06 | 3.52 | 3.34 |
Other Current Assets | - | 12.24 | 24.76 | 36.85 | 26.56 |
Total Current Assets | 796.61 | 585.43 | 855.15 | 1,605 | 942.34 |
Property, Plant & Equipment | 13.35 | 17.88 | 27.07 | 35.84 | 41.71 |
Other Intangible Assets | 230.56 | 20.46 | 23.17 | 26.01 | 28.76 |
Long-Term Accounts Receivable | 126.25 | - | - | - | - |
Long-Term Deferred Charges | - | 176.88 | 112.65 | 20.85 | - |
Total Assets | 1,167 | 800.64 | 1,018 | 1,687 | 1,013 |
Accounts Payable | 66.29 | 37.62 | 86.97 | 62.48 | 53.36 |
Accrued Expenses | 121.14 | 97.89 | 116.54 | 100.32 | 78.22 |
Short-Term Debt | 136.87 | - | - | - | - |
Current Portion of Leases | 8.28 | 7.68 | 7.5 | 7.17 | 6.89 |
Current Income Taxes Payable | 1.83 | 2.71 | 1.6 | 0.6 | - |
Current Unearned Revenue | - | 16.33 | 41.47 | 40.43 | 24.96 |
Other Current Liabilities | 76.26 | 93.45 | 66.91 | 53.71 | 7.79 |
Total Current Liabilities | 410.66 | 255.69 | 320.99 | 264.71 | 171.22 |
Long-Term Debt | 785.68 | 1,065 | 844.9 | 762.6 | - |
Long-Term Leases | 3 | 6.68 | 14.36 | 21.33 | 28.49 |
Long-Term Unearned Revenue | 1.61 | - | - | 29.5 | 47.02 |
Long-Term Deferred Tax Liabilities | 0.26 | 0.17 | 0.37 | 0.41 | 0.43 |
Other Long-Term Liabilities | 49.71 | 63.3 | 5.3 | 5.95 | 8.08 |
Total Liabilities | 1,251 | 1,390 | 1,186 | 1,084 | 255.24 |
Common Stock | -84.13 | 67.81 | 55.03 | 55.03 | 46.34 |
Additional Paid-In Capital | - | 3,451 | 3,083 | 3,022 | 2,573 |
Retained Earnings | - | -4,110 | -3,303 | -2,471 | -1,860 |
Treasury Stock | - | - | -2.36 | -2.59 | -1.86 |
Comprehensive Income & Other | - | 0.94 | -0.41 | 0.01 | 0.13 |
Shareholders' Equity | -84.13 | -589.83 | -167.88 | 602.91 | 757.57 |
Total Liabilities & Equity | 1,167 | 800.64 | 1,018 | 1,687 | 1,013 |
Total Debt | 933.82 | 1,079 | 866.77 | 791.09 | 35.38 |
Net Cash (Debt) | -232.73 | -673.73 | -134.71 | 705.09 | 853.58 |
Net Cash Growth | - | - | - | -17.40% | -37.81% |
Net Cash Per Share | -2.87 | -10.72 | -2.56 | 15.70 | 19.19 |
Filing Date Shares Outstanding | 101.76 | 67.81 | 52.67 | 52.44 | 44.47 |
Total Common Shares Outstanding | 101.76 | 67.81 | 52.67 | 52.44 | 44.47 |
Working Capital | 385.95 | 329.74 | 534.16 | 1,340 | 771.12 |
Book Value Per Share | -0.83 | -8.70 | -3.19 | 11.50 | 17.03 |
Tangible Book Value | -314.7 | -610.29 | -191.05 | 576.9 | 728.81 |
Tangible Book Value Per Share | -3.09 | -9.00 | -3.63 | 11.00 | 16.39 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.